{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-231197","form_type":"8-K","ticker":null,"cik":"0001718108","company_name":"Surface Oncology, Inc.","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.972109+00:00","generated_at":"2026-06-10T22:15:39.819625+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","5.07","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Coherus closes acquisition of Surface Oncology for ~$66.9M; adds IL-27 and CCR8 assets","bullets":["Coherus issued 0.1960 shares per Surface share for a total value of ~$66.9M ($40M plus $26.9M net cash of Surface).","Surface shareholders received CVRs for 70% of Novartis/GSK program milestones and 25-50% of ex-US licensing payments for CHS-114 and casdozokitug.","Acquisition adds clinical-stage assets: toripalimab (anti-PD-1), casdozokitug (IL-27), CHS-114 (CCR8), and CHS-006 (TIGIT).","Surface common stock delisted from Nasdaq effective prior to market open on September 8, 2023; now wholly owned subsidiary of Coherus."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-231197","json":"https://secwatch.observer/filing/0001193125-23-231197.json","markdown":"https://secwatch.observer/filing/0001193125-23-231197.md","text":"https://secwatch.observer/filing/0001193125-23-231197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/d525254d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:15:39.819625+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12473ca02e","claim":"Jessica Fees departed as other_named_officer at Surface Oncology, Inc..","evidence_excerpt":"In addition, Robert W. Ross, M.D., Jessica Fees, Chandra Adams, Vito J. Palombella, Ph.D., Henry Rath and Alison O’Neil ceased to serve as officers of the Company pursuant to the Merger Agreement, effective as of immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"128093e255","claim":"Henry Rath departed as other_named_officer at Surface Oncology, Inc..","evidence_excerpt":"In addition, Robert W. Ross, M.D., Jessica Fees, Chandra Adams, Vito J. Palombella, Ph.D., Henry Rath and Alison O’Neil ceased to serve as officers of the Company pursuant to the Merger Agreement, effective as of immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"1a10ddeaa1","claim":"Robert W. Ross, M.D. departed as other_named_officer at Surface Oncology, Inc..","evidence_excerpt":"In addition, Robert W. Ross, M.D., Jessica Fees, Chandra Adams, Vito J. Palombella, Ph.D., Henry Rath and Alison O’Neil ceased to serve as officers of the Company pursuant to the Merger Agreement, effective as of immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"2a71e11043","claim":"Denice Torres departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"39d0eb6726","claim":"Chandra Adams departed as other_named_officer at Surface Oncology, Inc..","evidence_excerpt":"In addition, Robert W. Ross, M.D., Jessica Fees, Chandra Adams, Vito J. Palombella, Ph.D., Henry Rath and Alison O’Neil ceased to serve as officers of the Company pursuant to the Merger Agreement, effective as of immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"547189a402","claim":"Laurie D. Stelzer departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6fe0aca3eb","claim":"David S. Grazel, M.D. departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"7a19366f55","claim":"Benjamin Hickey departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"90e2a6b73d","claim":"Alison O’Neil departed as other_named_officer at Surface Oncology, Inc..","evidence_excerpt":"In addition, Robert W. Ross, M.D., Jessica Fees, Chandra Adams, Vito J. Palombella, Ph.D., Henry Rath and Alison O’Neil ceased to serve as officers of the Company pursuant to the Merger Agreement, effective as of immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"9c0316fa45","claim":"J. Jeffrey Goater departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a229f812b2","claim":"Armen B. Shanafelt, Ph.D. departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a84e9ae5e4","claim":"Ramy Ibrahim, M.D. departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ab85d488f2","claim":"Elliott Sigal, M.D., Ph.D. departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b5bd531cda","claim":"Robert W. Ross, M.D. departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c54928795d","claim":"Vito J. Palombella, Ph.D. departed as other_named_officer at Surface Oncology, Inc..","evidence_excerpt":"In addition, Robert W. Ross, M.D., Jessica Fees, Chandra Adams, Vito J. Palombella, Ph.D., Henry Rath and Alison O’Neil ceased to serve as officers of the Company pursuant to the Merger Agreement, effective as of immediately prior to the Effective Time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"}],"fact_type":"executive_change"},{"claim_id":"eb1c058210","claim":"Carsten Brunn, Ph.D. departed as Director at Surface Oncology, Inc..","evidence_excerpt":"At the Effective Time, pursuant to the terms of the Merger Agreement, each of J. Jeffrey Goater, David S. Grazel, M.D., Ramy Ibrahim, M.D., Carsten Brunn, Ph.D., Benjamin Hickey, Robert W. Ross, M.D., Armen B. Shanafelt, Ph.D., Elliott Sigal, M.D., Ph.D., Laurie D. Stelzer and Denice Torres ceased serving as directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f056692c7676c6b5c495e4e5d8cd6ac1cbf22ddd","claim":"Surface Oncology, Inc. underwent a change of control involving Coherus BioSciences, Inc. for $66.9 million (closed 2023-09-08).","evidence_excerpt":"employee equity awards (which exchange ratio was calculated based on a $5.2831 per share price of Coherus common stock) for a total value equal to approximately $66.9 million, the sum of $40 million plus Surface’s net cash at closing of the transaction of $26.9 million. Surface shareholders also received contingent value rights (CVRs) for 70% of","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Coherus BioSciences, Inc."},{"label":"Consideration","value":"$66.9 million"},{"label":"Closing","value":"2023-09-08"}],"fact_type":"ma_transaction"},{"claim_id":"91b77324c390ec6cc684565b3c59bb4fdcc9f436","claim":"Surface Oncology, Inc. shareholders approved Approval of the Merger Proposal at the 2023-09-07 meeting.","evidence_excerpt":"The Company’s stockholders approved the proposal to adopt the Merger Agreement (the “ Merger Proposal ”). The Merger Proposal was approved by the requisite vote of the Company’s stockholders. The following votes were cast at the Special Meeting (in person or by proxy): Votes For Votes Against Abstentions Broker Non-Votes 40,908,190 683,979 66,868 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"merger approval"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-07"}],"fact_type":"shareholder_vote"},{"claim_id":"93b61fe9a72e22573f170da0678db1dc3c868a30","claim":"Surface Oncology, Inc. shareholders approved Approval of the Advisory, Non-Binding Compensation Proposal at the 2023-09-07 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation that will or may be paid to the Company’s named executive officers in connection with the Mergers (the “ Advisory Compensation Proposal ”). The Advisory Compensation Proposal was approved by the requisite vote of the Company’s stockholders. The following votes were cast at the Special Meeting (in person or by proxy): Votes For Votes Against Abstentions Broker Non-Votes 26,592,107 10,199,559 4,867,371 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1718108/000119312523231197/0001193125-23-231197-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-09-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}